Experts warn of rapid physician disenchantment as sales forces swell in India
This article was originally published in Scrip
Rapid sales force expansions in underserved emerging markets like India are expected to improve market penetration significantly, but experts caution that any potential sales force 'arms race' could lead to a 'downward spiral' of physician disenchantment and higher cost of sales.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.